title: [Polymyalgia rheumatica: What is the current status?].
abstract: The diagnosis of polymyalgia rheumatica (PMR) is based on the typical clinical symptoms and elevated inflammatory markers in blood; however, both are unspecific and the differential diagnosis of the disease still represents a challenge for clinicians. The new consensus classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established in 2012 have a high sensitivity (92.6 %) and specificity (91.2 %) and therefore contribute to improved diagnostics. Glucocorticoids are still the standard treatment with methotrexate and as an alternative and possibly anti-interleukin (anti-IL) 6 therapy in the future.
authors.affiliation: Universitätsklinik für Rheumatologie, Immunologie & Allergologie, Inselspital, Freiburgstrasse 18, 3010, Bern, Schweiz, michael.seitz@insel.ch.
authors.forename: M
authors.initials: M
authors.lastname: Seitz
mesh_terms: D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood*; D003937:Diagnosis, Differential; D005060:Europe; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage*; D011111:Polymyalgia Rheumatica / Q000175:diagnosis* / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012219:Rheumatology / Q000592:standards*; D014481:United States; D000093242:Interleukin-6 Inhibitors
chemical_list: D015415:Biomarkers; D016207:Cytokines; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008727:Methotrexate; D000093242:Interleukin-6 Inhibitors